John Owen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John Owen has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Mary Ann Knovich
Department of Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina
2 shared publicationsAli S. Wahla
Section on Pulmonary and Critical Care, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
1 shared publicationBharathi Upadhya
Department of Internal Medicine
1 shared publicationBrent J. Shelton
Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, North Carolina
1 shared publicationDavid C. Sane
Section on Cardiology, Wake Forest University School of Medicine, Winston Salem, NC, USA
1 shared publicationDoug Case
1 shared publication
Latest Publications
- 1 December 2010
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 33 (3) , 267-271
BsaXI/RFLP analysis of initial or selectively reamplified PCR product is unreliable in detecting the V617F mutation in JAK2
P>Introduction: Laboratory testing for the presence of the V617F mutation in JAK2 has taken on great importance in the diagnosis of myeloproliferative disorders. The availability of a facile detection method would bring this testing into greater clinical use. The polymerase chain reaction coupled with restriction fragment length polymorphisms is such a facile method. BsaXI cleaves the normal sequence but does not cleave the sequence leading to the V617F mutation. Methods: We have examined the use of selective PCR reamplification with BsaXI cleavage to enrich the fraction of V617F and compared the assignment of mutation with an established qPCR method. Results: We found that BsaXI fails to completely cleave normal sequence PCR product, leading to false positivity, particularly at low mutation levels. We also found that first-round standard PCR introduces new mutations in which subsequent reamplification and digestion cannot distinguish from the V617F mutation. Conclusion: This combination of problems effectively combines to render selective reamplification and redigestion unsuitable for detecting low fractions of the V617F mutation.
- 1 December 2010
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 33 (3) , 267-271
BsaXI/RFLP analysis of initial or selectively reamplified PCR product is unreliable in detecting the V617F mutation in JAK2
P>Introduction: Laboratory testing for the presence of the V617F mutation in JAK2 has taken on great importance in the diagnosis of myeloproliferative disorders. The availability of a facile detection method would bring this testing into greater clinical use. The polymerase chain reaction coupled with restriction fragment length polymorphisms is such a facile method. BsaXI cleaves the normal sequence but does not cleave the sequence leading to the V617F mutation. Methods: We have examined the use of selective PCR reamplification with BsaXI cleavage to enrich the fraction of V617F and compared the assignment of mutation with an established qPCR method. Results: We found that BsaXI fails to completely cleave normal sequence PCR product, leading to false positivity, particularly at low mutation levels. We also found that first-round standard PCR introduces new mutations in which subsequent reamplification and digestion cannot distinguish from the V617F mutation. Conclusion: This combination of problems effectively combines to render selective reamplification and redigestion unsuitable for detecting low fractions of the V617F mutation.
- 15 September 2008
- Published by Wiley in European Journal of Haematology
- Vol. 81 (4) , 311-316
Myocardial infarction in thrombotic thrombocytopenic purpura: a single‐center experience and literature review
Background: Several case reports and series have described myocardial infarctions (MIs) in patients hospitalized for thrombotic thrombocytopenic purpura (TTP). The exact magnitude and outcome of this complication are unknown.Methods: Electronic medical records for patients admitted to Wake Forest University Baptist Medical Center were examined from 1996 to 2005. Those patients having a diagnosis of TTP during the hospitalization period were included in the analysis. Only patients’ initial episodes of TTP were analyzed. Baseline cardiac and TTP risk factors were documented. Outcomes analyzed included MIs, arrhythmias, development of congestive heart failure and death.Results: Eighty‐five patients diagnosed with TTP were identified with 13 (15.3%) having MIs, as defined by an elevation of cardiac enzymes. Median troponin I value was 5.9 ng/mL (range 3.7–8.8 ng/mL). Twelve patients had non‐ST segment elevation MIs and one had ST segment elevation. Two of 13 patients who had echocardiographic analysis had documented wall motion abnormalities. There was no difference between non‐MI and MI patients in cardiac risk factors, prior cardiac events, history of thromboembolic disease or heart failure. There was no in‐hospital mortality difference.Conclusion: MI is an important complication of TTP, identified in 15.3% of patients in our study. Routine cardiovascular evaluation with cardiac enzymes, electrocardiography, and telemetry is warranted in acute TTP patients. Appropriate intervention is yet to be determined.
- 15 September 2008
- Published by Wiley in European Journal of Haematology
- Vol. 81 (4) , 311-316
Myocardial infarction in thrombotic thrombocytopenic purpura: a single‐center experience and literature review
Background: Several case reports and series have described myocardial infarctions (MIs) in patients hospitalized for thrombotic thrombocytopenic purpura (TTP). The exact magnitude and outcome of this complication are unknown.Methods: Electronic medical records for patients admitted to Wake Forest University Baptist Medical Center were examined from 1996 to 2005. Those patients having a diagnosis of TTP during the hospitalization period were included in the analysis. Only patients’ initial episodes of TTP were analyzed. Baseline cardiac and TTP risk factors were documented. Outcomes analyzed included MIs, arrhythmias, development of congestive heart failure and death.Results: Eighty‐five patients diagnosed with TTP were identified with 13 (15.3%) having MIs, as defined by an elevation of cardiac enzymes. Median troponin I value was 5.9 ng/mL (range 3.7–8.8 ng/mL). Twelve patients had non‐ST segment elevation MIs and one had ST segment elevation. Two of 13 patients who had echocardiographic analysis had documented wall motion abnormalities. There was no difference between non‐MI and MI patients in cardiac risk factors, prior cardiac events, history of thromboembolic disease or heart failure. There was no in‐hospital mortality difference.Conclusion: MI is an important complication of TTP, identified in 15.3% of patients in our study. Routine cardiovascular evaluation with cardiac enzymes, electrocardiography, and telemetry is warranted in acute TTP patients. Appropriate intervention is yet to be determined.
- Open Access
- 24 October 2003
- Published by Wiley in American Journal of Hematology
- Vol. 74 (3) , 170-174
Overweight individuals are at increased risk for thrombotic thrombocytopenic purpura
Our understanding of the pathophysiology of thrombotic thrombocytopenic purpura, TTP, has increased dramatically in the past few years with the identification of the role of ADAMTS13. Nonetheless, risk factors for the development of acute TTP are few. Informally, obesity was felt to be common in patients with TTP and so a formal study was undertaken to further define this association. We report our data in 105 patients with classical TTP as defined by thrombocytopenia and microangiopathic hemolytic anemia. We found that marked obesity is a previously unrecognized risk factor with an associated odds ratio of 7.6. Interestingly, despite this increased risk, obesity might well be associated with lower mortality, although this did not reach statistical significance. Am J. Hematol. 74:170–174, 2003.
- 24 October 2003
- Published by Wiley in American Journal of Hematology
- Vol. 74 (3) , 170-174
Open AccessOverweight individuals are at increased risk for thrombotic thrombocytopenic purpura
Our understanding of the pathophysiology of thrombotic thrombocytopenic purpura, TTP, has increased dramatically in the past few years with the identification of the role of ADAMTS13. Nonetheless, risk factors for the development of acute TTP are few. Informally, obesity was felt to be common in patients with TTP and so a formal study was undertaken to further define this association. We report our data in 105 patients with classical TTP as defined by thrombocytopenia and microangiopathic hemolytic anemia. We found that marked obesity is a previously unrecognized risk factor with an associated odds ratio of 7.6. Interestingly, despite this increased risk, obesity might well be associated with lower mortality, although this did not reach statistical significance. Am J. Hematol. 74:170–174, 2003.
- 1 January 2003
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 89 (04) , 768-769
Inappropriate use of positive predictive value in describing the rapid collagen binding assay for von Willebrand factor cleaving protease
- 1 January 2003
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 89 (04) , 768-769
Inappropriate use of positive predictive value in describing the rapid collagen binding assay for von Willebrand factor cleaving protease